NEWS
Live from the Event | Shengnuo Biopharm Makes a Splash at the 93rd API China, Leading the Future in Peptides
The 93rd API China kicked off successfully in Chongqing on November 12, with Shengnuo Biopharm (Booth N5 Hall 5L25) getting off to a strong start on the first day. The exhibition floor was buzzing with professional exchanges, as the company's demonstration of its integrated, end-to-end capabilities in peptide APIs and CDMO services attracted numerous industry professionals for in-depth discussions and garnered widespread recognition. The exhibition is still ongoing, and we sincerely invite colleagues from across the industry to visit our booth to continue the dialogue and explore collaborative opportunities.
Chongqing, China – November 12, 2025 – The 93rd China International Pharmaceutical Raw Materials, Intermediates, Packaging, and Equipment Trade Fair (API China 2025) grandly opened today at the Chongqing International Expo Center. As a leading enterprise in the peptide field, Chengdu Shengnuo Biopharm Co., Ltd. (Stock Code: 688117) made an impressive appearance at Booth 5L25, Hall N5. Leveraging its exceptional technical expertise and comprehensive integrated solutions, the company attracted numerous industry experts, clients, and partners for discussions on the very first day, creating a vibrant atmosphere.
Professional Exchanges: Discussing the Future of Peptides
From the outset, Shengnuo Biopharm's booth was filled with a spirit of professional dialogue. The company's specialized team, drawing on its profound technical background, engaged visiting guests in in-depth discussions regarding the technical features and application prospects of products like peptide APIs and cosmetic active peptides. Through detailed technical documentation and expert explanations, the team systematically showcased Shengnuo's extensive technical heritage in peptide R&D and manufacturing, earning high praise from visitors. The meeting areas remained bustling throughout the day, with productive conversations unfolding around technical specifics and potential collaboration.
"We highly value the opportunity to connect with industry peers on this professional platform that API China provides," stated a Shengnuo Biopharm representative on site. "The energetic level of engagement on day one is truly encouraging. It not only reflects the strong market demand for high-quality peptide solutions but also underscores Shengnuo's technical influence within the sector."
Technical Strength Gains Industry Recognition
At this exhibition, Shengnuo Biopharm highlighted its integrated service capabilities spanning "from drug discovery to commercial manufacturing." Visitors showed particular interest in the company's strengths in the following areas:
- R&D and Innovation Prowess: Over 20 years dedicated to the peptide field, supported by a robust R&D system and a professional team.
- Quality Management System: Strict adherence to GMP standards, ensuring product quality and regulatory compliance.
- CDMO Service Capabilities: Providing end-to-end support from R&D through to industrialization.
After gaining deeper insights into the company's technical pathways and project experience, multiple clients expressed clear recognition of Shengnuo Biopharm's professional capabilities and indicated definite interest in future collaboration.
The Exhibition Continues - Your Visit is Welcome
The excitement of API China 2025 continues. Over the next two days (November 13-14), the Shengnuo Biopharm team will remain at Booth 5L25, Hall N5 to welcome your visit. We look forward to:
Engaging in deeper exchanges about technological advancements in the peptide field.
Exploring cooperation opportunities in APIs and CDMO services.
Joining hands to foster development and jointly create a new future for the peptide industry.
If you missed us on the first day, please feel free to contact us via the following methods.
About Shengnuo Biopharm:
Chengdu Shengnuo Biopharm Co., Ltd. is a "Specialized, Refined, Unique, and Innovative" high-tech enterprise and a publicly listed company focused on the peptide industry. Its business encompasses the R&D, production, and sales of peptide active pharmaceutical ingredients (APIs), cosmetic active peptides, CDMO services, and peptide formulation products. With integrated R&D and manufacturing capabilities stretching from advanced intermediates and APIs to finished formulations, Shengnuo is committed to becoming a trusted global partner in the peptide pharmaceutical field.
Contact Us:
Website: www.snbiopharmacy.com
Tel & WhatsApp: +86 18116577817
Email: sinobiopharm@gmail.com
Chengdu Shengnuo Biopharm Co., Ltd.
November 12, 2025
Hot news
Shengnuo Bio has signed a strategic agreement with a Brazilian "Belt and Road" institution to cooperate on the supply of peptide APIs, technology exchange, and market channel development, with a focus on promoting GLP-1 class APIs such as Semaglutide and Tirzepatide in the Brazilian market. This collaboration marks the extension of the company's overseas presence into the core South American market and provides a practical pathway for China-Brazil biomedical cooperation under the "Belt and Road" framework.
2025-12-08
The 93rd API China kicked off successfully in Chongqing on November 12, with Shengnuo Biopharm (Booth N5 Hall 5L25) getting off to a strong start on the first day. The exhibition floor was buzzing with professional exchanges, as the company's demonstration of its integrated, end-to-end capabilities in peptide APIs and CDMO services attracted numerous industry professionals for in-depth discussions and garnered widespread recognition. The exhibition is still ongoing, and we sincerely invite colleagues from across the industry to visit our booth to continue the dialogue and explore collaborative opportunities.
2025-11-12
Chengdu Shengnuo Biopharm sincerely invites you to attend the 93rd China International Pharmaceutical Raw Materials, Intermediates, Packaging, and Equipment Trade Fair (API China 2025). Join us from November 12–14, 2025, at Booth No. 5L25, Hall N5, Chongqing International Expo Center, as we explore cutting-edge technologies and collaboration opportunities in the peptide sector.
2025-11-11
October 30, 2025 – Chengdu Shengnuo Biopharm Co., Ltd. held the project commencement ceremony in Dayi Economic Development Zone, marking the official start of construction for the Semaglutide, Tirzepatide, and other peptide Active Pharmaceutical Ingredient (API) industrialization base project.
2025-10-31